This ETF offers much more of a mid-cap tilt than other health-care ETFs. As such, we believe it provides purer exposure to the U.S. health-care sector than do some of its peers, whose holdings include large-cap pharmaceutical companies with meaningful overseas businesses.
Our equity analysts expect health-care spending in China to grow meaningfully during the next five to 10 years as China ages and becomes richer.
Utilization rates have turned a corner and are rising, although they still haven’t reached the levels where they were in 2007. Read more